Nelarabine Added to Chemotherapy Shows Encouraging Results in Children with T-ALL

Share this content:
(ChemotherapyAdvisor) –Nelarabine added to an intensive modified Berlin-Frankfurt-Münster (BFM) 86-based chemotherapy regimen produced “encouraging results” and was well tolerated in children newly diagnosed with high-risk T-cell acute lymphoblastic leukemia (T-ALL), according to results of a study published online June 25 in the Journal of Clinical Oncology.

These results were demonstrated particularly in patients with a slow early response, “who have historically fared poorly,” noted Kimberly Dunsmore, MD, of the Children's Oncology Group and University of Virginia Health Sciences Center, Charlottesville, VA; and colleagues.

“Overall, 75% to 80% of children with T-ALL are cured with contemporary chemotherapy regimens,” they write. “However, the salvage rate is extremely poor for patients who relapse. Thus, to improve survival for children with T-ALL, it is essential to identify effective agents that can be incorporated into first-line chemotherapy regimens. The most powerful predictor of poor outcome in T-ALL is a poor early chemotherapy response….”

The Children's Oncology Group pilot study was conducted in two stages. In stage one, 8 patients with a slow early response by prednisone poor response (PPR; ≥1,000 peripheral blood blasts on day 8 of prednisone prephase) received chemotherapy plus 6 courses of nelarabine 400 mg/m2 once per day; 4 patients with slow early response by high minimal residual disease (MRD; ≥1% at day 36 of induction) received chemotherapy plus 5 courses of nelarabine and 16 patients with a rapid early response received chemotherapy without nelarabine.

In stage two, all patients received six 5-day courses of nelarabine at 650 mg/m2 once per day (10 patients with slow early response [1 by MRD, 9 by PPR]) or 400 mg/m2 once per day (38 patients with rapid early response and 12 with slow early response [3 by MRD, 9 by PPR]).

Five-year event-free survival rates were 73% for 11 stage one slow early response patients and 67% for 22 stage two slow early response patients treated with nelarabine vs 69% for 16 stage one rapid early response patients treated without nelarabine and 74% for 38 stage two rapid early response patients treated with nelarabine.

For all patients receiving nelarabine (n=70), 5-year event-free survival was 73% vs 69% for those treated without nelarabine (n=16). The only significant difference in toxicities was decreased neutropenic infections in patients treated with nelarabine, 42%, vs 81% in those who did not receive nelarabine.

Based on these results, the Children's Oncology Group is currently conducting a randomized phase 3 trial of chemotherapy with and without nelarabine 650 mg/m2 in children, adolescents, and young adults with T-ALL. Given “significant concerns about the potential for neurotoxicity,” each is being carefully monitored for this adverse effect, they reported.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs